• Hilary A. Capell
  • T. J. Daymond
  • W. Carson Dick
Part of the Treatment in Clinical Medicine book series (TC MEDICINE)


Corticosteroids have been used and abused in many conditions since their dramatic debut in 1948. This brief chapter will emphasise their toxicity, which may be considerable with prolonged use, while attempting to highlight indications for their prescription. Much of the relevant literature on the subject is more than 10 years old, and despite 30 years of use corticosteroids still exemplify the confusion and controversy which surround drug therapy in rheumatology.


Rheumatic Disease Migration Inhibitory Factor Giant Cell Arteritis Mixed Connective Tissue Disease Polymyalgia Rheumatica 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Further Reading

  1. Askeri M, Vigios PJ Jr, Moskowitz RW (1976) Steroid myopathy in connective tissue diseases. Am J Med 61: 485–492CrossRefGoogle Scholar
  2. Bacon PA, Myles AB, Berntwell CG, Daly JR, Savage O (1966) Corticosteroid withdrawal in rheumatoid arthritis. Lancet II: 935–937Google Scholar
  3. Castles J J (1979) Clinical pharmacology of glucocorticoids. In: Hollander JL, McCarty DJ Jr (eds) Arthritis and allied conditions, 9th edn. Lea and Febiger, PhiladelphiaGoogle Scholar
  4. David DS, Grieco MH, Cushman P (1970) Adrenal glucocorticoids after twenty years. A review of their clinical relevant consequences. J Chronic Dis 22: 637–711PubMedCrossRefGoogle Scholar
  5. Fauci AS, Dale DC, Barlow JE (1976) Glucocorticosteroid therapy; mechanisms of action and clinical considerations. Ann Intern Med 84: 304–315PubMedGoogle Scholar
  6. Haynes RC, Murad F (1980) Adrenocorticotrophic hormone, adrenocortical steroids and their synthetic analogues. In: Goodman WS, Gillman AC (eds) The pharmacological basis of therapeutics, 6th edn. Macmillan, New York, pp 1466–1496Google Scholar
  7. Jasani MK, Boyle JA, Dick WC, Williamson J, Taylor AK, Buchanan WW (1968) Corticosteroid induced H.P.A. axis suppression. Ann Rheum Dis 27: 352–359PubMedCrossRefGoogle Scholar
  8. Koch-Weser J, Buyny RL (1976) Withdrawal from glucocorticoid therapy. N Engl J Med 295: 30–32CrossRefGoogle Scholar
  9. Nuki G, Jasani MK, Downie WW, Whaley K, Dick WC, Williamson J, Paterson RWW, Boyle C, Buchanan WW (1970) Clinicopharmacological studies on depot tetracosactrin in patients with rheumatoid arthritis. Pharm Clin 2: 99–108CrossRefGoogle Scholar
  10. Williamson J, Paterson RWW, McGavin DDM et al. (1969) Posterior subcapsular cataracts and glaucoma associated with long term oral corticosteroid therapy. Br J Ophthalmol 53: 361–372PubMedCrossRefGoogle Scholar
  11. Zutschi DW, Friedman M, Ansell BM (1971) Corticotrophin therapy in juvenile chronic polyarthritis ( Still’s disease) and effect on growth. Arch Dis Child 46: 584–593CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1983

Authors and Affiliations

  • Hilary A. Capell
    • 1
  • T. J. Daymond
    • 2
  • W. Carson Dick
    • 3
    • 4
  1. 1.Centre for Rheumatic DiseasesGlasgowScotland
  2. 2.Sunderland District General HospitalSunderlandEngland
  3. 3.University of Newcastle upon TyneEngland
  4. 4.Royal Victoria InfirmaryNewcastle upon TyneEngland

Personalised recommendations